

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virginia 22313-1450 www.unpto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/584,024	04/30/2008	Valerie Frankard	1187-31	4438
28249 7590 02/14/2011 DILWORTH & BARRESE, LLP			EXAMINER	
1000 WOODBURY ROAD			COLLINS, CYNTHIA E	
SUITE 405 WOODBURY	NY 11797		ART UNIT	PAPER NUMBER
	,		1638	
			MAIL DATE	DELIVERY MODE
			02/14/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice to Comply

Application No.	Applicant(s)
0584024	FRANKARD ET AL.
xaminer	Art Unit
Cynthia Collins	1638

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

/C Pri	/Cynthia Collins/ Primary Examiner, Art Unit 1638				
PL	PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY				
	Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845 Patentln Software is Available At www.USPTO.gov				
	For CRF Submission Help, call (571) 272-2510 Patentin Software Program Support				
FC	For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (571) 272-0731 or (571) 272-0951				
	A statement that the content of the paper and computer readable copies are the same and, winclude no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(c) or 1.821(d) or				
⊠	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specific its entry into the application.	ally directing			
	Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".				
	7. Other:				
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the Listing" as required by 37 C.F.R. 1.821(e).	"Sequence			
	5. The computer readable form that has been filed with this application has been found to be dam unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer remust be submitted as required by 37 C.F.R. 1.825(d).				
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, a the attached copy of the marked -up "Raw Sequence Listing."				
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required 37 C.F.R. 1.821(e).	by			
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequent required by 37 C.F.R. 1.821(c).	nce Listing" as			
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applical directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	May 15, 1990).			
	The nucleotide and/or amino acid sequence disclosure contained in this application does not comply w requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):	vith the			

U.S. Patent and Trademark Office Part of Paper No. 20110204